Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Pancreatic Cancer | Research article

Silencing of FTX suppresses pancreatic cancer cell proliferation and invasion by upregulating miR-513b-5p

Authors: Shan Li, Qian Zhang, Wen Liu, Chunbo Zhao

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Abnormal expression of long non-coding RNA (lncRNA) FTX (five prime to Xist), which is involved in X chromosome inactivation, has been reported in various tumors. However, the effect of FTX on the development of pancreatic cancer (PC) has not been elucidated. The purpose of this study was to explore the possible molecular mechanism of FTX in PC.

Methods

Quantitative real-time PCR (qRT-PCR) was used to measure the expression levels of FTX and miR-513b-5p in PC cell lines. Proliferation and apoptosis of PC cells were determined by CCK-8, Edu assay, and flow cytometry. Invasion and migration ability of PC cells were detected by Transwell assay and scratch test. Bioinformatics analysis, luciferase reporter gene assay, and RNA immunoprecipitation (RIP) assay were used to verify the direct binding between FTX and miR-513b-5p. The xenotransplantation mouse model was established to explore the effect of FTX and miR-513b-5p on the PC tumor growth in vivo.

Results

The expression levels of FTX were increased in PC cell lines, and silencing of FTX remarkably suppressed the invasion ability and cell viability. Besides, FTX could bind to miR-513b-5p as a competitive endogenous RNA, thus promoting the invasion and proliferation ability of PC cells. Moreover, knockdown of FTX inhibited the tumor growth and increased the expression levels of miR-513b-5p and apoptosis-related proteins in vivo.

Conclusions

FTX could directly combine with miR-513b-5p as a competitive endogenous RNA, thus promoting the occurrence and development of PC in vitro and in vivo.
Appendix
Available only for authorised users
Literature
1.
Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47.PubMedCrossRef
2.
Panni R, Herndon J, Knolhoff B, Hogg G, Gupta V, Fields R, et al. CD11b hyperactivation improves response to immunotherapy in pancreatic cancer. HPB. 2018;20:S536–S7.CrossRef
3.
Chien W, Ding L, Sun Q, Torres-Fernandez L, Tan S, Xiao J, et al. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget. 2014;5(13):4881–94.PubMedPubMedCentralCrossRef
4.
Chien W, Sudo M, Ding L, Sun Q, Wuensche P, Lee K, et al. Functional genome-wide screening identifies targets and pathways sensitizing pancreatic Cancer cells to Dasatinib. J Cancer. 2018;9(24):4762–73.PubMedPubMedCentralCrossRef
5.
6.
Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, et al. International Association of Pancreatology (IAP)/European pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16(1):14–27.PubMedCrossRef
7.
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525.PubMedPubMedCentralCrossRef
8.
Takano S, Reichert M, Bakir B, Das KK, Nishida T, Miyazaki M, et al. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev. 2016;30(2):233–47.PubMedPubMedCentralCrossRef
9.
von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 2015;27(4):561–73.CrossRef
10.
Krebs AM, Mitschke J, Losada ML, Schmalhofer O, Boerries M, Busch H, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19(5):518.PubMedCrossRef
11.
Ito H, Tanaka S, Akiyama Y, Shimada S, Adikrisna R, Matsumura S, et al. Dominant expression of DCLK1 in human pancreatic cancer stem cells accelerates tumor invasion and metastasis. PLoS One. 2016;11(1):e0146564.PubMedPubMedCentralCrossRef
12.
Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med. 2017;9(384):eaai8504.PubMedPubMedCentralCrossRef
13.
Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK, et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas. 2015;44(5):693.PubMedPubMedCentralCrossRef
14.
Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci. 2017;114(38):10202–7.PubMedCrossRefPubMedCentral
15.
Pandya G, Kirtonia A, Sethi G, Pandey A, Garg M. The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential. Biochim Biophys Acta Rev Cancer. 1874;2020(2):188423.CrossRef
16.
Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47.PubMedCrossRef
17.
Engreitz JM, Ollikainen N, Guttman M. Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol. 2016;17(12):756.PubMedCrossRef
18.
19.
Pang E-J, Yang R. Fu X-b, Liu Y-f. overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biol. 2015;36(4):2403–7.CrossRef
20.
Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13(1):84.PubMedPubMedCentralCrossRef
21.
Cheng Y, Jutooru I, Chadalapaka G, Corton JC, Safe S. The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget. 2015;6(13):10840.PubMedPubMedCentralCrossRef
22.
Pan Y, Li C, Chen J, Zhang K, Chu X, Wang R, et al. The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem. 2016;40(1–2):219–29.PubMedCrossRef
23.
Yang Y, Zhang J, Chen X, Xu X, Cao G, Li H, et al. LncRNA FTX sponges miR-215 and inhibits phosphorylation of vimentin for promoting colorectal cancer progression. Gene Ther. 2018;25(5):321–30.PubMedCrossRef
24.
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y, et al. Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma. Oncotarget. 2016;7(18):25350–65.PubMedPubMedCentralCrossRef
25.
He X, Sun F, Guo F, Wang K, Gao Y, Feng Y, et al. Knockdown of Long noncoding RNA FTX inhibits proliferation, migration, and invasion in renal cell carcinoma cells. Oncol Res. 2017;25(2):157–66.PubMedPubMedCentralCrossRef
26.
27.
Yonemori K, Kurahara H, Maemura K, Natsugoe S. MicroRNA in pancreatic cancer. J Hum Genet. 2017;62(1):33.PubMedCrossRef
28.
Muti P, Donzelli S, Sacconi A, Hossain A, Ganci F, Frixa T, et al. MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast Cancer: the ORDET prospective study. Carcinogenesis. 2017.
29.
Higuchi T, Todaka H, Sugiyama Y, Ono M, Tamaki N, Hatano E, et al. Suppression of miR-7 biogenesis by NF90-NF45 controls cell proliferation in hepatocellular carcinoma. J Biol Chem. 2016;M116:748210.
30.
Hu Y, Qin X, Yan D, Cao H, Zhou L, Fan F, et al. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. Tumor Biol. 2017;39(3):1010428317691659.CrossRef
31.
Crossland RE, Norden J, Bibby LA, Davis J, Dickinson AM. Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine. J Immunol Methods. 2016;429:39–49.PubMedCrossRef
32.
Guo P, Li N, Fan L, Lu J, Liu B, Zhang B, et al. Study of penetration mechanism of labrasol on rabbit cornea by Ussing chamber, RT-PCR assay, Western blot and immunohistochemistry. Asian J Pharm Sci. 2018.
33.
Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000;403(6765):98–103.PubMedCrossRef
34.
Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–7.PubMedPubMedCentralCrossRef
35.
Chittiboyina S, Chen Z, Chiorean EG, Kamendulis LM, Hocevar BA. The role of the folate pathway in pancreatic cancer risk. PLoS One. 2018;13(2):e0193298.PubMedPubMedCentralCrossRef
36.
Zhao L, Kong H, Sun H, Chen Z, Chen B, Zhou M. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol. 2018;233(5):4044–55.PubMedCrossRef
37.
Zhou Y, Chen Y, Ding W, Hua Z, Wang L, Zhu Y, et al. LncRNA UCA1 impacts cell proliferation, invasion, and migration of pancreatic cancer through regulating miR-96/FOXO3. IUBMB Life. 2018;70(4):276–90.PubMedCrossRef
38.
Li X, Zhao Q, Qi J, Wang W, Zhang D, Li Z, et al. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARgamma pathway in hepatocellular carcinoma. Int J Oncol. 2018;53(2):551–66.PubMedPubMedCentral
39.
Sadeghi Ekbatan S, Li X-Q, Ghorbani M, Azadi B, Kubow S. Chlorogenic acid and its microbial metabolites exert anti-proliferative effects, S-phase cell-cycle arrest and apoptosis in human colon cancer caco-2 cells. Int J Mol Sci. 2018;19(3):723.PubMedCentralCrossRef
40.
Khanam R, Kumar R, Hejazi II, Shahabuddin S, Meena R, Jayant V, et al. Piperazine clubbed with 2-azetidinone derivatives suppresses proliferation, migration and induces apoptosis in human cervical cancer HeLa cells through oxidative stress mediated intrinsic mitochondrial pathway. Apoptosis. 2018;23(2):113–31.PubMedCrossRef
41.
Ma Z-J, Lu L, Yang J-J, Wang X-X, Su G, Wang Z-l, et al. Lariciresinol induces apoptosis in HepG2 cells via mitochondrial-mediated apoptosis pathway. Eur J Pharmacol. 2018;821:1–10.PubMedCrossRef
42.
Wang S, Long S, Xiao S, Wu W, Hann SS. Decoction of Chinese herbal medicine Fuzheng Kang-Ai induces lung cancer cell apoptosis via STAT3/Bcl-2/caspase-3 pathway. Evid Based Complement Alternat Med. 2018;2018.
43.
Salvamoser R, Brinkmann K, O'Reilly LA, Whitehead L, Strasser A, Herold MJ. Characterisation of mice lacking the inflammatory caspases-1/11/12 reveals no contribution of caspase-12 to cell death and sepsis. Cell Death Differ. 2019;26(6):1124–37.PubMedCrossRef
44.
Mao L, Le S, Jin X, Liu G, Chen J, Hu J. CSN5 promotes the invasion and metastasis of pancreatic cancer by stabilization of FOXM1. Exp Cell Res. 2019;374(2):274–81.PubMedCrossRef
45.
Singh SK, Mishra MK, Eltoum I-EA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018;8(1):1323.PubMedPubMedCentralCrossRef
46.
Ma M, Cai B, Jiang L, Abdalla BA, Li Z, Nie Q, et al. lncRNA-Six1 Is a Target of miR-1611 that Functions as a ceRNA to Regulate Six1 Protein Expression and Fiber Type Switching in Chicken Myogenesis. Cells. 2018;7(12):243.PubMedCentralCrossRef
47.
Wei DM, Jiang MT, Lin P, Yang H, Dang YW, Yu Q, et al. Potential ceRNA networks involved in autophagy suppression of pancreatic cancer caused by chloroquine diphosphate: a study based on differentially-expressed circRNAs, lncRNAs, miRNAs and mRNAs. Int J Oncol. 2019;54(2):600–26.PubMed
48.
Zhou J, Liu M, Chen Y, Xu S, Guo Y, Zhao L. Cucurbitacin B suppresses proliferation of pancreatic cancer cells by ceRNA: effect of miR-146b-5p and lncRNA-AFAP1-AS1. J Cell Physiol. 2019;234(4):4655–67.PubMedCrossRef
49.
Zhang W, Bi Y, Li J, Peng F, Li H, Li C, et al. Long noncoding RNA FTX is upregulated in gliomas and promotes proliferation and invasion of glioma cells by negatively regulating miR-342-3p. Lab Investig. 2017;97(4):447–57.PubMedCrossRef
50.
Liu F, Yuan JH, Huang JF, Yang F, Wang TT, Ma JZ, et al. Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene. 2016;35(41):5422–34.PubMedCrossRef
51.
Das Gupta A, Chen K-H, Wu D, Hoskin V, Mewburn J, Lima P, et al. Mitochondrial Drp1 Binding Partners MiD49 and MiD51 Are Epigenetically Upregulated in Lung Cancer: A Novel Mitochondrial-Targeted Approach to Cell Cycle Regulation and Cancer Therapy. In: B68 ONCOGENIC MUTATIONS, METASTASIS, AND NOVEL THERAPEUTICS: American Thoracic Society; 2019. p. A3952-A.CrossRef
52.
Boettcher AN, Kiupel M, Adur M, Cocco E, Santin A, Charley S, et al. Abstract LB-042: successful tumor formation following xenotransplantation of primary human ovarian cancer cells into severe combined immunodeficient (SCID) pigs. AACR; 2018.
53.
Draz H, Goldberg AA, Tomlinson Guns ES, Fazli L, Safe S, Sanderson JT. Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model. Investig New Drugs. 2018;36(4):718–25.CrossRef
54.
Tureci M-KR, Woll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2019;8(1):e1523096.PubMedCrossRef
55.
Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, et al. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep. 2018;8(1):12248.PubMedPubMedCentralCrossRef
56.
Fricke IB, De Souza R, Costa Ayub L, Francia G, Kerbel R, Jaffray DA, et al. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. PLoS One. 2018;13(5):e0196892.PubMedPubMedCentralCrossRef
Metadata
Title
Silencing of FTX suppresses pancreatic cancer cell proliferation and invasion by upregulating miR-513b-5p
Authors
Shan Li
Qian Zhang
Wen Liu
Chunbo Zhao
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07975-6

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research article

Extracellular vesicles-derived microRNA-222 promotes immune escape via interacting with ATF3 to regulate AKT1 transcription in colorectal cancer

Research article

Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer

Research article

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Research article

The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome

Research article

Exploratory analysis of lateral pelvic sentinel lymph node status for optimal management of laparoscopic lateral lymph node dissection in advanced lower rectal cancer without suspected lateral lymph node metastasis

Research

A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits